Lupin’s $90 Million Astellas Settlement: Navigating the Complexities of Pharmaceutical Patent Litigation
India’s Lupin Limited recently settled a protracted patent infringement dispute with Japan’s Astellas Pharma in the United States, agreeing to pay $90 million to resolve claims related to Astellas’s blockbuster prostate cancer drug, Xtandi (enzalutamide). This significant financial resolution, announced to the market, aims to conclude the legal battle over Lupin’s proposed generic version of […]